An experimental therapy in development by Shire for patients with the rare blood disorder hereditary thrombotic thrombocytopenic purpura (hTTP) has been granted a fast track designation by the US Food and Drug Administration.
US regulators have placed Shire’s SHP626 on a fast-track regulatory pathway in the hope of potentially accelerating access to the experimental liver disease drug.